Gwanpyo Koh

Dr. Gwanpyo Koh

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2020 in Journal of Obesity & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
JMJaecheol Moon
Jaecheol Moon
GKGwanpyo Koh
Gwanpyo Koh
Jaecheol Moon, Gwanpyo Koh. J Obes Metab Syndr 2020;29:166-73. https://doi.org/10.7570/jomes20028

1 June 2013 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
SLSang Ah Lee
Sang Ah Lee
YKYoung Ah Kim
Young Ah Kim
EYEun Jin Yang
Eun Jin Yang
EKEun-Jeong Kwon
Eun-Jeong Kwon
SKSun Hyung Kim
Sun Hyung Kim
DLDae Ho Lee
Dae Ho Lee
Context: Dipeptidyl peptidase 4 (CD26/DPP4) is expressed on blood T cells and also circulates in a soluble form (sCD26/DPP4).Objective: We aimed to evaluate blood T cell and circulating CD26/DPP4 and its association with metabolic parameters in patients with type 2 diabetes mellitus (T2DM).Designs: We measured CD26/DPP4 expression (percentage of CD26+ cells using flow cytometry) on CD4+ and CD8+ T cells, serum CD26/DPP4 level and activity, and various metabolic parameters in T2DM patients not on DPP4 inhibitor therapy (n = 148). Nondiabetic subjects (n = 50) were included as a control group.Results: Compared with the healthy controls, CD26/DPP4 expression on CD4+ T cells and CD8+ T cells was higher in T2DM patients. Serum CD26/DPP4 levels and enzymatic activities were also higher in patients with T2DM than in the control group only when metformin and/or thiazolidinedione-treated T2DM patients were excluded; metformin and/or thiazolidinedione-treated T2DM patients had lower values compared with other T2DM patients. Various parameters in T2DM patients were related to CD26/DPP4 expression on the T cells (hemoglobin A1c), serum sCD26/DPP4 (hemoglobin A1c and insulin resistance assessed by updated homeostasis model assessment), and serum CD26/DPP4 activity (insulin resistance assessed by updated homeostasis model assessment, γ-glutamyl transferase, and alanine aminotransferase) by multivariate analyses. After active glucose control for 12 weeks in drug-naive T2DM patients (n = 50), CD26/DPP4 expression on blood T cells was significantly decreased.Conclusions: Our results suggest that the CD26/DPP4 level on blood T cells was associated with glucose control status in patients with T2DM.

1 March 2012 in Metabolism
Verified
Journal Article
Closed access
WKWonyoung Kang
Wonyoung Kang
HHHyun Ju Hong
Hyun Ju Hong
JGJian Guan
Jian Guan
DKDong Geon Kim
Dong Geon Kim
EYEun-Jin Yang
Eun-Jin Yang
DLDae-Ho Lee
Dae-Ho Lee

4 April 2003 in Phytochemistry
Verified
Journal Article
Closed access
KSKwang Sik Suh
Kwang Sik Suh
GKGwanpyo Koh
Gwanpyo Koh
Cheol-Young ParkCheol-Young Park
Cheol-Young Park
JWJeong Taek Woo
Jeong Taek Woo
SKSung Woon Kim
Sung Woon Kim
YKYoung Seol Kim
Young Seol Kim

1 January 2009 in Korean Diabetes Journal
Verified
Journal Article
Open access
PDF file
SLSoo Lim
Soo Lim
DKDae Jung Kim
Dae Jung Kim
ACand Se-Young Choung
and Se-Young Choung
HSHyun Shik Son
Hyun Shik Son
CCChoon Hee Chung
Choon Hee Chung
In-Kyu LeeIn-Kyu Lee
In-Kyu Lee

12 July 2014 in Diabetes Care
Verified
Journal Article
Closed access
PDF file
SLSang Ah Lee
Sang Ah Lee
SCSuk Ju Cho
Suk Ju Cho
MJMyung Ho Jeong
Myung Ho Jeong
YKYoung Jo Kim
Young Jo Kim
CKChong Jin Kim
Chong Jin Kim
ORon behalf of the KAMIR/KorMI Registry
on behalf of the KAMIR/KorMI Registry
OBJECTIVE: We aimed to evaluate the association between hypoglycemia at admission and 30-day mortality in patients with acute myocardial infarction (AMI) and to determine whether these associations differed according to diabetes-control status in AMI patients with diabetes. RESEARCH DESIGN AND METHODS: We analyzed the prognostic significance of hypoglycemia and hyperglycemia in 34,943 AMI patients with or without type 2 diabetes from two AMI registries: the Korea Acute Myocardial Infarction Registry (KAMIR) and the Korea Working Group on Myocardial Infarction (KorMI). RESULTS: The patients were divided into five groups according to serum-glucose levels at admission: <3.9 mmol/L (<70 mg/dL); 3.9–7.72 mmol/L (70–139 mg/dL); 7.78–11.06 mmol/L (140–199 mg/dL); 11.11–14.39 mmol/L (200–259 mg/dL); and ≥14.44 mmol/L (≥260 mg/dL). The 30-day mortality rates in the lowest and highest glucose groups were higher than those in other groups; the lowest glucose group had the highest mortality for patients with type 2 diabetes, after adjusting for multiple factors. We also extracted and compared four subgroups from the patients with type 2 diabetes, based on hemoglobin A1c and serum-glucose levels at admission: group A, <6.5% (48 mmol/mol) and <3.9 mmol/L; group B, <6.5% (48 mmol/mol) and ≥11.11 mmol/L; group C, ≥8% (64 mmol/mol) and <3.9 mmol/L; and group D, ≥8% (64 mmol/mol) and ≥11.11 mmol/L. Group C had the highest 30-day mortality rate among the groups. CONCLUSIONS: These data suggest that hypoglycemia at admission affects clinical outcomes differently in AMI patients with type 2 diabetes depending on the diabetes-control status.